首页|Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Chronic liver disease(CLD)entails elevated risk of COVID-19 severity and mortality.The effectiveness of the booster dose of inactivated SARS-CoV-2 vaccine in stimulating antibody response in CLD patients is unclear.Therefore,we conducted a cross-sectional study involving 237 adult CLD patients and 170 healthy controls(HC)to analyze neutralizing antibodies(NAbs)against SARS-CoV-2 prototype and BA.4/5 variant,anti-receptor binding domain(RBD)IgG,and total anti-SARS-CoV-2 antibodies.Serum levels of the total anti-SARS-CoV-2 antibodies,anti-RBD IgG and inhibition efficacy of NAbs were significantly elevated in CLD patients after the booster dose compared with the pre-booster dose,but were relatively lower than those of HCs.Induced humoral responses decreased over time after booster vaccination.The neutralization efficiency of the serum against BA.4/5 increased but remained below the inhibition threshold.All four SARS-CoV-2 antibodies,including total anti-SARS-CoV-2 antibodies,anti-RBD IgG and NAbs against prototype and BA.4/5,were lower in patients with severe CLD than those with non-severe CLD.After booster shot,age and time after the last vaccine were the risk factors for seropositivity of NAb against BA.4/5 in CLD patients.Additionally,white blood cell counts and hepatitis B core antibodies were the protective factors,and severe liver disease was the risk factor associated with seropositivity of total anti-SARS-CoV-2 antibodies.Overall,our data uncovered that antibody responses were improved in CLD patients and peaked at 120 days after the booster vaccines.All antibodies excepting total anti-SARS-CoV-2 antibodies declined after peak.CLD patients exhibited impaired immunologic responses to vaccination and weakened NAbs against BA.4/5,which hindered the protective effect of the booster shot against Omicron prevalence.Cellular immune responses should be further evaluated to determine the optimal vaccine regimen for CLD patients.

Chronic liver disease(CLD)SARS-CoV-2 inactivated vaccinesBooster vaccinationAntibody responseImmune response

Yongmei Liu、Jianhua Lu、Haoting Zhan、Wenfang Yuan、Xiaomeng Li、Haiyan Kang、Haolong Li、Yongliang Chen、Linlin Cheng、Xingli Sun、Haojie Zheng、Wei Wang、Erhei Dai、Yongzhe Li

展开 >

Department of Clinical Laboratory,State Key Laboratory of Complex,Severe and Rare Diseases,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing,100730,China

Department of Clinical Laboratory,The Fifth Hospital of Shijiazhuang,Hebei Medical University,Shijiazhuang,050021,China

Division of Liver Diseases,The Fifth Hospital of Shijiazhuang,Hebei Medical University,Shijiazhuang 050021,China

Department of Clinical Laboratory,Peking University People's Hospital,Beijing,100035,China

展开 >

Beijing Natural Science FoundationNational Key Research and Development Program of ChinaBeijing Municipal Science & Technology CommissionNational High Level Hospital Clinical Research FundingKey Research and Development Plan of Hebei Province,Special Health Innovation Project

M230082018YFE0207300Z2111000025210212022-PUMCH-B-12422377744D

2023

10.1016/j.virs.2023.07.005

中国病毒学
中国科学院武汉病毒研究所，中国微生物学会

中国病毒学

CSTPCDCSCD
影响因子：0.393
ISSN：1674-0769
年,卷(期)：2023.38(5)
  • 49